Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 26, 2026Acta Medica (Hradec Kralove Czech Republic)Open Access

Are We Moving Toward Curative Approaches in Chronic Lymphocytic Leukemia?

View Full Paper
Ask AI
Bookmark
Share

Authors

MŠMartin ŠimkovičUniversity Hospital Hradec KrálovéEVEva VejražkováCharles UniversityDÉDominika Écsiová

Discussion

Loading...

Member takes

Implication

This review demonstrates improved survival in CLL through targeted therapies, indicating a shift towards curative strategies.

Key Points

  • The aim is to explore advancements in the treatment of chronic lymphocytic leukemia and their implications for care.
  • Review of recent clinical trials and treatments for CLL
  • Analysis of targeted therapies, including BTK and BCL-2 inhibitors
  • Evaluation of MRD-guided treatment cessation strategies
  • Discussion on the role of biomarkers and patient-specific factors in therapy selection
  • BTK inhibitors like ibrutinib show durable disease control and improved safety.
  • Venetoclax with anti-CD20 antibodies can lead to MRD-negative remissions.
  • Combining BTK and BCL-2 inhibition may provide chemotherapy-free responses.
  • Ongoing studies are optimizing treatment sequencing and addressing acquired resistance.

Cite This Study

Šimkovič et al. (2025) studied this question.

synapsesocial.com/papers/69c4cd12fdc3bde448918f42https://doi.org/10.14712/18059694.2026.1
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1miR-15 and miR-16 induce apoptosis by targeting BCL22005 · 3,546 citations
  2. 2Final analysis of the RESONATE-2 study: up to 10 years of follow-up of first-line ibrutinib treatment for CLL/SLL2025 · 41 citations
  3. 3Serious Infections in Patients Receiving Ibrutinib for Treatment of Lymphoid Cancer2018 · 270 citations
  4. 4Subcutaneous Epcoritamab in Patients with Richter's Syndrome: Early Results from Phase 1b/2 Trial (EPCORE CLL-1)2022 · 45 citations
  5. 5Immune restoration with ibrutinib plus venetoclax in first-line chronic lymphocytic leukemia: the phase 2 CAPTIVATE study2023 · 20 citations